Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $24,750.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 990 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $25.00, for a total transaction of $24,750.00. Following the completion of the sale, the chief financial officer directly owned 148,121 shares of the company’s stock, valued at $3,703,025. The trade was a 0.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Scott Blumberg also recently made the following trade(s):

• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total value of $838,805.36.

CeriBell Stock Performance

Shares of CBLL stock opened at $24.20 on Friday. The stock has a market capitalization of $928.80 million, a PE ratio of -13.75 and a beta of 0.81. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33. The stock’s 50-day moving average price is $19.54 and its 200 day moving average price is $19.22. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. As a group, equities research analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Analyst price targets increased. BTIG Research raised its target from $28 to $30 and reiterated a Buy rating, while Canaccord Genuity lifted its target from $25 to $26 and also maintained a Buy rating. These revisions indicate continued confidence in CeriBell’s growth prospects. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional interest has been supportive. TimesSquare Capital Management initiated a position valued at approximately $15.2 million, while KCM Capital increased its holdings by 40% to 1.4 million shares. Additional firms also established or expanded positions, suggesting some professional investors see value in CBLL.
• Neutral Sentiment: Recent financial results were mixed. CeriBell’s quarterly revenue of $28.1 million exceeded the $27.28 million consensus estimate, but its $0.51 per-share loss was wider than the expected $0.47 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $1.96 per share.
• Neutral Sentiment: Analyst opinion remains generally favorable but valuation expectations are uneven. The consensus rating is “Moderate Buy,” although the average target of $22.40 is below the recent trading level. Barclays upgraded the stock to Neutral, reflecting a more cautious stance.
• Negative Sentiment: Senior executives sold a substantial number of shares. CEO Xingjuan Chao sold 33,614 shares for about $841,000 across August 18–19, reducing her holdings by roughly 4%. CFO Scott Blumberg sold 34,502 shares for approximately $864,000, cutting his direct ownership by about 18.45%. The transactions occurred around $25 per share, close to CeriBell’s 52-week high, and could be interpreted as profit-taking or a potential near-term confidence signal. CeriBell Insider Trading Activity

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. BTIG Research raised their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group lifted their target price on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Barclays raised shares of CeriBell to a “neutral” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $22.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new stake in CeriBell in the 1st quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd increased its position in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of CeriBell in the third quarter worth $33,000. CWM LLC lifted its position in shares of CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after acquiring an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.